Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Insmed Inc. Revenue & Financial Statements
Insmed Inc. reported revenue of $606.4M for the fiscal year ended December 31, 2025, up 66.7% year over year, with net income of $(1.3B) and diluted EPS of $-6.42.
- Company
- Insmed Inc. INSM · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 188.5M | 245.4M | 305.2M | 363.7M | 606.4M |
| Cost of revenue | 44.2M | 55.1M | 65.6M | 85.7M | 122.9M |
| Gross profit | 144.3M | 190.2M | 239.6M | 278.0M | 483.5M |
| Operating income | (375.1M) | (457.3M) | (709.6M) | (878.3M) | (1.2B) |
| Pretax income | (348.8M) | (406.3M) | (666.2M) | (814.5M) | (153.3M) |
| Net income | (434.7M) | (481.5M) | (749.6M) | (913.8M) | (1.3B) |
| Diluted EPS | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 |
| EBITDA | (366.0M) | (452.0M) | (704.1M) | (872.3M) | (1.2B) |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.5M | 90.3M | 93.4M | 104.4M | 92.8M | 107.4M | 142.3M | 263.8M |
| Cost of revenue | 17.5M | 21.0M | 21.2M | 26.2M | 21.3M | 28.1M | 29.4M | 44.2M |
| Gross profit | 58.0M | 69.4M | 72.3M | 78.3M | 71.5M | 79.3M | 113.0M | 219.6M |
| Operating income | (145.5M) | (288.9M) | (213.4M) | (230.4M) | (248.1M) | (312.9M) | (366.0M) | (319.7M) |
| Pretax income | (156.5M) | (299.8M) | (219.5M) | (234.3M) | (255.7M) | (320.4M) | (368.7M) | (326.9M) |
| Net income | (157.1M) | (300.6M) | (220.5M) | (235.5M) | (256.6M) | (321.7M) | (370.0M) | (328.5M) |
| Diluted EPS | -1.06 | -1.94 | -1.27 | -1.30 | -1.42 | -1.70 | -1.75 | -1.53 |
| EBITDA | (143.9M) | — | (212.0M) | (228.9M) | (246.3M) | — | (363.5M) | (316.1M) |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 1.2B | 1.7B | 1.3B | 2.0B | 2.3B |
| Current assets | 837.0M | 1.3B | 929.1M | 1.6B | 1.8B |
| Cash & equivalents | 716.8M | 1.1B | 482.4M | 555.0M | 510.4M |
| Total liabilities | 833.0M | 1.6B | 1.7B | 1.7B | 1.5B |
| Current liabilities | 135.2M | 190.2M | 225.6M | 297.5M | 468.9M |
| Long-term debt | 566.6M | 1.1B | 1.2B | 1.1B | 541.0M |
| Total debt | 566.6M | 1.1B | 1.2B | 1.1B | 541.0M |
| Stockholders’ equity | 410.5M | 88.0M | (331.9M) | 285.4M | 739.0M |
| Net debt | (150.2M) | 51.2M | 672.9M | 548.4M | 30.5M |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | (363.3M) | (400.4M) | (536.2M) | (683.9M) | (935.0M) |
| Investing cash flow | (64.3M) | (34.6M) | (223.6M) | (583.2M) | (64.6M) |
| Financing cash flow | 612.5M | 793.3M | 168.4M | 1.3B | 954.1M |
| Capital expenditure | 7.3M | 9.9M | 13.3M | 21.9M | 32.6M |
| Free cash flow | (370.6M) | (410.3M) | (549.5M) | (705.8M) | (967.6M) |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 46.0M | 57.7M | 74.8M | 96.8M | 152.7M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every INSM filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.